Press Releases

Press Releases

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)

May 2, 2022

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)

TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022

April 29, 2022

TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022

TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder

April 19, 2022

TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 24, 2022

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures

March 17, 2022

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures

TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference

March 11, 2022

TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference

TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022

March 9, 2022

TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

March 1, 2022

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

February 24, 2022

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19

January 27, 2022

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19

Displaying 11 - 20 of 106
Top